Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: To assess predictive ability of serum interferon-inducible protein 10 (IP10) and hepatitis B core antibody (anti-HBc) levels for virological relapse (VR) and hepatitis B surface antigen (HBsAg) loss after nucleos(t)ide analog (NA) discontinuation.
Methods: In this multicenter prospective study, overall 139 patients were followed up for 24 months after NA discontinuation.
Results: End of treatment (EOT) IP10 and anti-HBc were 29.2 (5.1-66.4) pg/mL and 193.6 (136.9-221.4) IU/mL. EOT IP10 and anti-HBc were independent predictors for VR and HBsAg loss in Cox regression analysis. Cumulative rates of VR in patients with EOT IP10 > 26.99 pg/mL was 31.9% (vs. 70.1%, hazard ratio [HR] 2.998, p < 0.001). Cumulative incidences of VR in patients with EOT anti-HBc ≤141.35 IU/mL was 49.1% (vs. 60.6%, HR 2.99, p < 0.001). Cumulative probabilities of VR was 16.7% in patients with EOT IP10 > 26.99 pg/mL plus anti-HBc ≤141.35 IU/mL (vs. 73.6%, HR 6.464, p < 0.001). Cumulative probabilities of HBsAg loss in patients with EOT IP10 > 93.5 pg/mL was 46.2% (vs. 4.7%, HR 10.94, p < 0.001). Cumulative probabilities of HBsAg loss in patients with EOT anti-HBc ≤78.42 IU/mL were 47.1% (vs. 5%, HR 12.27, p < 0.001). Patients with EOT IP10 > 93.5 pg/mL plus anti-HBc ≤78.42 IU/mL had the highest 24-month cumulative HBsAg loss rate (53.8% vs. 4%, HR 16.83, p < 0.001).
Conclusion: High EOT IP10 and low EOT anti-HBc levels were related to both lower risk of VR and higher probability of HBsAg loss.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000533515 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure.
J Viral Hepat
October 2025
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Discontinuing antivirals in chronic hepatitis B virus (HBV) 'e' antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare.
View Article and Find Full Text PDFGlobal trends and insights in interferon therapy for chronic hepatitis B: a bibliometric analysis.
Virol J
September 2025
School of Clinical Medicine, Chengdu Medical College, Chengdu, 610500, Sichuan Province, China.
Background: Chronic hepatitis B (CHB) is a major global health issue, with interferon (IFN)-based therapy playing a key role in achieving sustained virological response and immune-mediated viral clearance. This study analyzed global research trends, collaborative networks, and emerging priorities in interferon therapy for CHB.
Methods: A comprehensive literature search was conducted using the Web of Science Core Collection database.
Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.
Aliment Pharmacol Ther
August 2025
St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Background And Aims: Discontinuing nucleos(t)ide analogues (NAs) may lead to functional cure (HBsAg loss) in selected patients with chronic hepatitis B (CHB). We evaluated the rates and predictors of HBsAg loss during long-term follow-up in a prospective cohort.
Methods: This real-world extension study followed participants from a prospective trial of NA discontinuation.
Coexistence of hepatitis B e antigen and antibody during antiviral treatment predicts better clinical outcomes in children.
J Pediatr Gastroenterol Nutr
August 2025
Department of Maternal and Child Health, Xiangya School of Public Health, Central South University, Changsha, China.
Objectives: The coexistence of hepatitis B e antigen (HBeAg) and hepatitis B e antibody (HBeAb) during antiviral therapy is considered atypical in patients with chronic hepatitis B (CHB), and its clinical implications remain inadequately understood, particularly in pediatric patients. This study aimed to investigate the clinical characteristics of this coexistence pattern and its impact on the outcomes of combined antiviral therapy in children with CHB.
Methods: A total of 254 treatment-naïve children diagnosed with HBeAg-positive CHB were retrospectively enrolled.
Anti-HBc IgM associates with acute flare and HBeAg/HBsAg loss in chronic hepatitis B patients with acute exacerbation.
Virulence
December 2025
Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China.
Acute exacerbation (AE) is common for patients with chronic hepatitis B (CHB). The aim of the study is to investigate the values of hepatitis B core antibody (anti-HBc) IgM in CHB-AE. Patients were screened from a prospective sub-cohort, 419 CHB patients with AE were enrolled and divided into groups according to antiviral treatment history, treatment naïve, withdrawal above or within 6 months, and on-treatment.
View Article and Find Full Text PDF